Shares of Protalix BioTherapeutics Inc. dipped 13.7 percent on Tuesday after the biotech unveiled a $115 million profit-sharing deal with Pfizer Inc. for Gaucher's disease drug Uplyso (taliglucerase alfa). (BioWorld Today)

There's a lot of talk these days about how the biotech industry's business models are broken.

BioCryst Pharmaceuticals Inc. priced a $49 million public offering, cashing in on the 593 percent gain its shares have posted so far this year thanks to progress with flu drug peramivir. (BioWorld Today)

Twice this month, biotechs that achieved their primary endpoints in a pivotal trial conducted under a special protocol assessment (SPA) found their drugs turned down by the FDA.